Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade

Table 3

The clinical factors in the responders (>40% PSA decrease) and nonresponders to second-line CAB therapy.

	Responders (40% PSA change)	Nonresponders	value
Number of patients (%)	10 (50%)	10 (50%)	—
Mean PSA at the diagnosis, ng/mL (range)	971.1 (23.8–5740)	548.9 (17.2–2590)	0.6
Mean nadir PSA after first-line CAB therapy, ng/mL (range)	1.69 (0.003–14.7)	3.16 (0.011–16.8)	0.059
Mean duration to nadir PSA after first-line CAB, months	13.9 (3–31)	12.4 (2–48)	0.32
Mean PSA at the start of second-line CAB therapy, ng/mL (range)	4.02 (0.116–20.7)	29.7 (0.114–116.3)	0.023
Mean duration of the response to second-line CAB therapy, months	17.2 (3–26)	—	—

CAB: combined androgen blockade.